Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Q: What type of study is this?

This is a Experimental Study study.

Michelle Melino; Wen Juan Tu; Helle Bielefeldt‐Ohmann; Martina Proctor; Taniya Ahuja; John Vandermeide; Amanda L. Bain; Gahyathiri Nallan; Sal Lee Goh; Thiru Prasanna; Jane E. Dahlstrom; Mariska Miranda; Ramesh Kumar Chaudhary; Aravind Anandam; Sumit Chaudhary; Jonathan T. Seal; Debottam Sinha; Shaoqian Zhang; Tam Hong Nguyen; Sriganesh Srihari; Günter Härtel; Amy Ives; Laeeq Malik; Desmond Yip; Michelle Nottage; Melissa Eastgate; Sudha Rao

doi:10.1158/1535-7163.30255334

Key Points

Dose de-escalation of paxalisib effectively reduces toxicity in combination treatments, enhancing patient tolerance.
Targeting ezh2 through pi3k-mtor inhibition significantly improves outcomes in triple-negative breast cancer models.
The study highlights the potential of combining immunotherapy with targeted therapies to overcome resistance.
Findings suggest a new approach for managing metastasis in triple-negative breast cancer, with implications for treatment protocols.

Implication

Dose de-escalation of PI3K–mTOR inhibitor paxalisib shows promise in overcoming toxicity, suggesting enhanced treatment strategies for triple-negative breast cancer.

Abstract

Supplementary Figure 2. Dose de-escalation of the PI3K-mTOR inhibitor, paxalisib, overcomes toxicity burden in combination treatments.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Melino et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a4c https://doi.org/10.1158/1535-7163.30255334

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers